CA2925008A1 - Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof - Google Patents

Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof Download PDF

Info

Publication number
CA2925008A1
CA2925008A1 CA2925008A CA2925008A CA2925008A1 CA 2925008 A1 CA2925008 A1 CA 2925008A1 CA 2925008 A CA2925008 A CA 2925008A CA 2925008 A CA2925008 A CA 2925008A CA 2925008 A1 CA2925008 A1 CA 2925008A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition
epinephrine
group
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2925008A
Other languages
English (en)
French (fr)
Inventor
John Scott Karolchyk
Mark L. Baum
Original Assignee
Imprimis Pharmaceuticals Inc
Harrow IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imprimis Pharmaceuticals Inc, Harrow IP LLC filed Critical Imprimis Pharmaceuticals Inc
Publication of CA2925008A1 publication Critical patent/CA2925008A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B65D25/02—Internal fittings
    • B65D25/04—Partitions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2925008A 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof Abandoned CA2925008A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361886269P 2013-10-03 2013-10-03
US61/886,269 2013-10-03
US201361892872P 2013-10-18 2013-10-18
US61/892,872 2013-10-18
US201461947778P 2014-03-04 2014-03-04
US61/947,778 2014-03-04
PCT/US2014/059077 WO2015051264A1 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof

Publications (1)

Publication Number Publication Date
CA2925008A1 true CA2925008A1 (en) 2015-04-09

Family

ID=52779188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925008A Abandoned CA2925008A1 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Country Status (10)

Country Link
US (4) US10993921B2 (enExample)
EP (1) EP3052095A4 (enExample)
JP (2) JP2016532723A (enExample)
KR (1) KR20160070077A (enExample)
AU (2) AU2014329412B2 (enExample)
BR (1) BR112016007328A2 (enExample)
CA (1) CA2925008A1 (enExample)
IL (1) IL244687A0 (enExample)
MX (1) MX2016004257A (enExample)
WO (1) WO2015051264A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12702651B2 (en) 2013-10-03 2026-08-11 Harrow Ip, Llc Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
BR112016007328A2 (pt) * 2013-10-03 2017-08-01 Imprimis Pharmaceuticals Inc composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
WO2017218918A1 (en) 2016-06-17 2017-12-21 Ys Pharmtech Stabilization of epinephrine formulations
WO2018039420A1 (en) * 2016-08-25 2018-03-01 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3687475A4 (en) * 2017-09-26 2021-07-28 YS Pharmtech STABILIZATION OF EPINEPHRIN FORMULATIONS
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3093725C (en) 2018-03-23 2021-08-24 Nevakar Inc. Epinephrine compositions and containers
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
US20230277694A1 (en) * 2022-03-04 2023-09-07 Harrow Ip, Llc Ophthalmic dye composition and method for administering same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) * 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines
US4590210A (en) * 1979-03-09 1986-05-20 Langham Maurice E Compositions for treatment of ocular hypertension
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
CA2002643A1 (en) * 1988-11-09 1990-05-09 Maryjane Helenek Antioxidant-free epinephrine solution for ophthalmic use
NL9102148A (nl) * 1991-12-20 1993-07-16 Dsm Nv Copolymeer van lacton en carbonaat en werkwijze voor het verkrijgen ervan.
WO1994008602A1 (en) * 1992-10-21 1994-04-28 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5709852A (en) 1995-12-05 1998-01-20 Basf Corporation Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends
WO1998003641A1 (en) 1996-07-23 1998-01-29 Crandall Wilson T Transdermal transport of molecules
FR2779061B1 (fr) * 1998-04-14 2004-08-20 Pharmatop Nouveau procede de stabilisation de composes phenoliques et les compositions pharmaceutiques en resultant
DE19859427A1 (de) 1998-12-22 2000-06-29 Beiersdorf Ag Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen
WO2000048662A1 (en) * 1999-02-16 2000-08-24 Prismedical Corporation Single dose delivery device
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
EP1531794B1 (en) * 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Inhalable epinephrine
ES2397574T3 (es) 2002-07-30 2013-03-08 Omeros Corporation Procedimiento y soluciones de irrigación oftalmológica
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20050176823A1 (en) 2004-02-10 2005-08-11 Diaz Robert L. Intra-operative procedure for post-operative pain control
FR2882930B1 (fr) * 2005-03-09 2009-03-27 Walid Katib Nouvelles compositions ophtalmologiques et leur mode d'utilisation
DE102005038368A1 (de) 2005-08-13 2007-02-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Doppelkammer-Behälter zur Lyophilisation, Verfahren zu dessen Befüllung und dessen Verwendung
US20070196324A1 (en) 2006-02-01 2007-08-23 Keefe Candace R Cellulite skin treatment methods and compositions
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2711001A3 (en) 2008-11-14 2014-07-02 Archer-Daniels-Midland Company Organogel compositions and processes for producing
CN101444481A (zh) 2009-01-06 2009-06-03 河北科技大学 不含抑菌剂的托吡卡胺滴眼液及其制备方法
WO2010139752A2 (en) * 2009-06-04 2010-12-09 Alk Ag Stabilised composition comprising at least one adrenergic compound
WO2011156803A2 (en) 2010-06-11 2011-12-15 Transdel Pharmaceuticals, Inc. Anti-cellulite composition and method of treating cellulite
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR20140112825A (ko) 2013-03-14 2014-09-24 삼성전자주식회사 전자 장치의 전자 결제 방법 및 장치
CA2915814A1 (en) 2013-06-18 2014-12-24 Harrow Ip, Llc Local use of pentoxifylline to treat peyronie's disease
WO2015006299A1 (en) 2013-07-08 2015-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of tranexamic acid and their use
BR112016007328A2 (pt) 2013-10-03 2017-08-01 Imprimis Pharmaceuticals Inc composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas
WO2018039420A1 (en) 2016-08-25 2018-03-01 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Also Published As

Publication number Publication date
US20170049721A1 (en) 2017-02-23
EP3052095A4 (en) 2017-07-05
US11045432B2 (en) 2021-06-29
US20210275471A1 (en) 2021-09-09
EP3052095A1 (en) 2016-08-10
KR20160070077A (ko) 2016-06-17
MX2016004257A (es) 2016-08-17
US10993921B2 (en) 2021-05-04
US20150119440A1 (en) 2015-04-30
JP2016532723A (ja) 2016-10-20
BR112016007328A2 (pt) 2017-08-01
AU2014329412A1 (en) 2016-05-05
JP2019142964A (ja) 2019-08-29
WO2015051264A8 (en) 2016-04-07
IL244687A0 (en) 2016-04-21
AU2014329412B2 (en) 2020-02-27
WO2015051264A1 (en) 2015-04-09
AU2020203044A1 (en) 2020-05-28
US20160354308A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
US20210275471A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US10285957B2 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
AU2011281035B2 (en) Acetycysteine compositions and methods of use thereof
JP2019517578A (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
RS62188B1 (sr) Stabilni midrijatski i anti-inflamatorni rastvori bez konzervansa za ubrizgavanje
JPH10502085A (ja) Ｉｏｐを制御するための医薬を含有する眼内潅注溶液
RU2532354C1 (ru) ИНЪЕКЦИОННАЯ ФОРМА 5α АНДРОСТАН-3β,5,6β-ТРИОЛА И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
CN102397246A (zh) 一种注射用磷丙泊酚钠及其制备方法和用途
JPH09506620A (ja) 非ステロイド抗炎症剤を含有する改良された眼内洗浄溶液
US20210346318A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20240058320A1 (en) Mydriatic compositions and methods for fabricating thereof
JP2022531670A (ja) インスリンプレミックスの配合物と製品、それを調製する方法、及びそれを使用する方法
US20250268976A1 (en) Broad-spectrum peptoids for treatment or prevention of wound infections, and compositions and methods of use thereof
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
CN101780096A (zh) 注射用丙泊酚磷酸酯及其制备方法和用途
WO2005041977A2 (en) Process for producing injectable gabapentin compositions
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190920

FZDE Discontinued

Effective date: 20220223